Folic Acid, Vit B9 / ROS Cancer Research Results

FA, Folic Acid, Vit B9: Click to Expand ⟱

Features:

B Vitamin supplement. Helps form red blood cells.
Folic acid (vitamin B9) is converted into tetrahydrofolate (THF) and its derivatives. These folate coenzymes are essential for one‐carbon transfer reactions, which are critical for the synthesis of purines and thymidylate—key components of DNA.

• Folate Deficiency and ROS: A deficiency in folic acid can exacerbate oxidative stress. Insufficient folate has been linked to increased ROS levels, which are capable of damaging cellular macromolecules, including DNA, proteins, and lipids. This oxidative DNA damage further increases mutation rates and contributes to carcinogenesis.

The evidence suggests that while adequate dietary folate is important for cancer prevention (by maintaining genomic stability and proper methylation), excessive folate supplementation in individuals with undiagnosed or existing neoplasms might be problematic.

-supplementation of folate may occur as folic acid, folinic acid or 5-methyltetrahydrofolate (5-MTHF).
-5-MTHF also known as L-methylfolate
-Naturally occurring 5-MTHF has important advantages over synthetic folic acid - it is well absorbed even when gastrointestinal pH is altered and its bioavailability is not affected by metabolic defects
-Use of 5-MTHF also prevents the potential negative effects of unconverted folic acid in the peripheral circulation
-Large RCT meta-analyses generally do not show a moderate increase in overall cancer incidence from folic acid during trial periods.
-High-dose folic acid has a long-running concern about “timing” (before vs after neoplasia), and NIH ODS cautions against >1,000 µg/day from supplements (UL) largely due to masking B12 deficiency and risk-uncertainty contexts.

-It’s best categorized as a “growth substrate / one-carbon cofactor” with high chemo-interaction relevance, not as a standalone anticancer natural product.

Folic acid, vitamin B9 — Folic acid is the synthetic, fully oxidized form of the water-soluble vitamin folate and is used in fortified foods, dietary supplements, deficiency treatment, pregnancy-related neural-tube-defect prevention, and selected oncology protocols. It is a nutritional vitamin and one-carbon metabolic precursor rather than a direct anticancer agent. Standard abbreviations include FA and vitamin B9; the broader term folate includes naturally occurring reduced folates, while 5-methyltetrahydrofolate, folinic acid and folic acid are chemically and clinically distinct forms. After intestinal absorption, folic acid must be reduced by dihydrofolate reductase to tetrahydrofolate derivatives that support purine synthesis, thymidylate synthesis, methionine regeneration and methyl-donor metabolism. In cancer, folate has a dual-context role: adequate status protects normal DNA synthesis and genomic stability, whereas folate availability can also support proliferation of established folate-dependent tumors. Folic acid should therefore be classified primarily as a nutritional one-carbon cofactor with major chemotherapy-interaction relevance, not as a standalone cancer treatment.

Primary mechanisms (ranked):

Supplies reduced folate cofactors for de novo thymidylate and purine synthesis required for DNA and RNA production.
Supports methionine synthase-dependent homocysteine remethylation and maintenance of methionine and S-adenosylmethionine-dependent methylation reactions.
Corrects folate deficiency, thereby reducing megaloblastic anemia, uracil misincorporation, chromosome instability and deficiency-associated oxidative stress.
Modifies antifolate chemotherapy toxicity and efficacy in a drug-, folate-form- and timing-dependent manner.
Reduces pemetrexed-associated hematologic and gastrointestinal toxicity when administered with vitamin B12 according to the treatment protocol.
Modulates neurologic and vascular effects indirectly through homocysteine reduction, particularly when baseline folate or vitamin B12 status is inadequate.

Bioavailability / PK relevance: Folic acid is generally well absorbed and has higher apparent bioavailability than naturally occurring food folates, but it requires enzymatic reduction before entering active one-carbon metabolism. Human dihydrofolate reductase activity is relatively limited and variable; larger or repeated doses can produce circulating unmetabolized folic acid. 5-Methyltetrahydrofolate enters the reduced-folate pool without requiring the initial dihydrofolate reductase steps, but evidence does not justify treating all folate forms as universally interchangeable. Folinic acid is a reduced folate used in specific oncology protocols and is not synonymous with ordinary folic acid supplementation.

In-vitro vs systemic exposure relevance: Cellular effects attributed to millimolar or high-micromolar folic acid exposure are generally not representative of nutritional systemic exposure. Physiologic effects are more accurately interpreted through intracellular folate sufficiency, enzyme saturation, folate transport, baseline deficiency and long-term one-carbon flux rather than acute direct cytotoxicity. Studies using folic-acid-conjugated nanoparticles evaluate folate-receptor targeting by the carrier and should not be interpreted as evidence that free folic acid has the same anticancer activity.

Clinical evidence status: Established clinical use for prevention and treatment of folate deficiency and prevention of neural tube defects; protocol-defined adjunct use with pemetrexed; extensive randomized evidence for homocysteine lowering; mixed and subgroup-dependent evidence for cognitive benefit; no established role as a standalone anticancer therapy. Randomized-trial meta-analyses have generally found no substantial overall increase or decrease in cancer incidence during approximately five years of supplementation, but uncertainty remains regarding dose, duration, baseline status and supplementation after neoplasia is established.

Folic Acid Mechanistic Profile

Rank	Pathway / Axis	Cancer Cells	Normal Cells	TSF	Primary Effect	Notes / Interpretation
1	One-carbon metabolism and nucleotide synthesis	↑ dTMP and purine synthesis capacity when folate-limited	↑ DNA synthesis, repair and hematopoietic cell production	R, G	Metabolic substrate support	Central biochemical function. Adequate folate protects normal genomic integrity but may also remove a growth constraint in established proliferating tumors.
2	Thymidylate synthase substrate axis	↑ availability of 5,10-methylene-THF for dTMP synthesis	↓ uracil misincorporation and chromosome breakage when deficiency is corrected	R, G	DNA precursor synthesis	This axis explains both the physiologic requirement for folate and the therapeutic rationale for antifolate drugs.
3	Methionine cycle and methylation capacity	↔ or altered DNA and histone methylation (context-dependent)	↑ methionine regeneration and methyl-donor homeostasis when folate-deficient	G	Epigenetic and metabolic regulation	Direction of gene-specific methylation effects cannot be generalized across tumor types or folate states.
4	Homocysteine remethylation	↓ homocysteine when folate-responsive	↓ homocysteine when folate or related B-vitamin status is limiting	G	Systemic metabolic correction	Requires adequate vitamin B12-dependent methionine synthase function. Homocysteine reduction is not itself evidence of anticancer efficacy.
5	Genomic stability during deficiency correction	↓ deficiency-associated DNA damage, but possible ↑ tumor substrate supply	↓ uracil incorporation, strand breaks and megaloblastic change	G	Deficiency correction	Produces a biologically plausible dual effect depending on whether folate deficiency precedes carcinogenesis or supplementation occurs after tumor establishment.
6	Oxidative stress during folate deficiency	↔ or ↓ ROS indirectly (context-dependent)	↓ deficiency-associated ROS and oxidative macromolecular injury	G	Secondary redox normalization	Folic acid is not primarily a direct antioxidant. Redox effects are secondary to improved one-carbon metabolism, glutathione-related metabolism and reduced homocysteine stress.
7	Pemetrexed toxicity modulation	↔ antitumor exposure when protocol supplementation is used	↓ myelosuppression and gastrointestinal toxicity	G	Required supportive supplementation	Oral folic acid plus intramuscular vitamin B12 is standard with pemetrexed. Current labeling specifies 400–1000 µg folic acid daily beginning before treatment and continuing after the final dose.
8	Methotrexate and reduced-folate interaction	Potential ↓ antifolate effect if folate rescue is incorrectly timed	Folinic acid ↑ rescue of normal tissues after high-dose methotrexate	R	Protocol-dependent rescue	Leucovorin is folinic acid, not folic acid. Rescue timing is critical and should not be generalized to self-directed folic acid supplementation.
9	Fluoropyrimidine chemosensitization	Folinic acid ↑ stabilization of thymidylate synthase inhibition	↑ gastrointestinal and marrow toxicity risk	R	Chemosensitization	This clinically established interaction involves folinic acid with 5-fluorouracil, not routine nutritional folic acid.
10	Folate receptor targeting	↑ uptake of folate-conjugated carriers in folate-receptor-positive models	Variable uptake according to receptor expression	P, R	Drug-delivery targeting ligand	Activity of folate-decorated nanoparticles belongs primarily to the payload and delivery system. It is not evidence of direct cytotoxicity by free folic acid.
11	Clinical Translation Constraint	Effect depends on tumor stage, folate status, dose, folate form and concurrent antifolate therapy	High intake may mask hematologic evidence of vitamin B12 deficiency	G	Dose and interpretation constraint	The adult tolerable upper intake level is 1,000 µg/day of folic acid from supplements and fortified foods, excluding medically supervised treatment. Folate status and vitamin B12 status should be interpreted together.

P: 0–30 min R: 30 min–3 hr G: >3 hr

Chemo Interaction Mini-Table

Drug / Regimen	Folate-Related Agent	Interaction Type	Mechanism (What’s happening)	Clinical Use / Practical Note	Net Effect
High-dose Methotrexate (HD-MTX)	Leucovorin (folinic acid; calcium folinate)	Rescue (toxicity mitigation)	Provides reduced folate to “rescue” normal cells from MTX-induced reduced-folate depletion; not given simultaneously because it can blunt MTX effect.	Standard component of HD-MTX supportive care (timing is protocol-defined; typically starts after MTX).	↓ toxicity while preserving efficacy when timed correctly :contentReference[oaicite:0]{index=0}
5-Fluorouracil (5-FU) regimens (e.g., colorectal protocols)	Leucovorin (folinic acid)	Potentiation (efficacy enhancement)	Increases and stabilizes thymidylate synthase (TS) inhibition by promoting formation of the inhibitory ternary complex (5-FU metabolite + TS + reduced folate cofactor).	Intentional synergy; also increases risk of GI and marrow toxicity vs 5-FU alone (protocol-dependent).	↑ efficacy + often ↑ toxicity :contentReference[oaicite:1]{index=1}
Pemetrexed (antifolate chemotherapy)	Folic acid (oral) + Vitamin B12 (IM)	Required supplementation (toxicity reduction)	Supplementation reduces severity of hematologic and GI toxicity during pemetrexed therapy.	Start before first dose, continue during treatment, and continue after last dose per label/protocol.	↓ toxicity (standard of care) :contentReference[oaicite:2]{index=2}
“Folic acid” vs “Leucovorin” (naming pitfall)	Folic acid (synthetic) vs Leucovorin (reduced folate)	Non-interchangeable	Leucovorin is a reduced folate used for MTX rescue and 5-FU potentiation; folic acid is mainly a nutritional supplement and not a direct substitute in these oncology protocols.	Use the specific agent indicated by protocol; don’t swap terms in notes.	Interpretation / protocol-critical :contentReference[oaicite:3]{index=3}
General supplementation safety note	High-dose folic acid supplements	Monitoring issue	Large folate intakes can mask hematologic signs of B12 deficiency while neurologic injury progresses.	Relevant when documenting “high-dose folate” use outside oncology protocols.	Safety constraint :contentReference[oaicite:4]{index=4}

Alzheimer’s disease relevance: Folic acid is not an established disease-modifying treatment for Alzheimer’s disease. Its strongest neurologic rationale is correction of folate deficiency and reduction of elevated homocysteine, usually in combination with vitamin B12 and sometimes vitamin B6. Randomized studies in mild cognitive impairment indicate that homocysteine-lowering B-vitamin combinations can slow brain atrophy or cognitive decline in selected participants, particularly those with elevated baseline homocysteine; other trials in unselected older adults or established dementia have been neutral. Small trials in mild cognitive impairment or Alzheimer’s disease have reported reductions in inflammatory markers and modest cognitive effects, but these findings are not sufficiently consistent for routine AD treatment recommendations. Vitamin B12 deficiency must be excluded or treated because folic acid can correct anemia while allowing B12-related neurologic injury to progress.

Primary mechanisms (ranked):

↓ plasma homocysteine through folate- and vitamin B12-dependent remethylation.
↓ homocysteine-associated vascular, excitotoxic and neurotoxic stress.
Preservation of methylation and phospholipid metabolism during folate deficiency.
Possible ↓ brain atrophy in mild cognitive impairment with elevated homocysteine when used as part of combined B-vitamin therapy.
Possible secondary ↓ inflammatory cytokines and oxidative stress in responsive or deficient populations.

Clinical evidence status: Small-to-moderate randomized trials and meta-analyses with mixed results. The most credible signal is subgroup-dependent benefit in mild cognitive impairment with elevated homocysteine rather than a general treatment effect in established Alzheimer’s disease.

Alzheimer’s Disease Mechanistic Profile

Rank	Pathway / Axis	Modulation	TSF	Primary Effect	Notes / Interpretation
1	Homocysteine remethylation	↓ homocysteine	G	Metabolic risk-factor reduction	Most reproducible biochemical effect. Clinical relevance is greatest when baseline homocysteine is elevated and vitamin B12 status is adequate.
2	Brain atrophy	↓ accelerated atrophy (subgroup-dependent)	G	Structural neuroprotection	Observed with combined folic acid, vitamin B12 and vitamin B6 in selected mild cognitive impairment populations; not established for folic acid alone.
3	Cognitive decline	↓ decline or ↔ (trial-dependent)	G	Possible cognitive preservation	Benefits appear more likely in participants with elevated homocysteine or low B-vitamin status. Several trials in broader populations have been neutral.
4	Methylation and phospholipid metabolism	↑ methyl-donor support when deficient	G	Neuronal metabolic support	Mechanistically plausible but not a validated surrogate for clinical AD modification.
5	Neuroinflammation	↓ IL-6, TNF-α and related markers (study-dependent)	G	Secondary anti-inflammatory effect	Reported in several small trials; replication and clinical importance remain uncertain.
6	Amyloid-related biomarkers	↔ or ↓ (model-dependent)	G	Exploratory biomarker modulation	Human evidence is limited and inconsistent. This should not be classified as established amyloid-targeted therapy.
7	Oxidative stress	↓ secondary oxidative injury when deficiency or hyperhomocysteinemia is corrected	G	Indirect redox support	Not primarily a direct radical-scavenging mechanism.
8	Clinical Translation Constraint	Benefit depends on baseline homocysteine, folate status, vitamin B12 status, disease stage and combined formulation	G	Patient-selection constraint	Evidence from combined B-vitamin regimens cannot be assigned specifically to folic acid. Established dementia has shown less consistent response than selected mild cognitive impairment.

P: 0–30 min R: 30 min–3 hr G: >3 hr

ROS, Reactive Oxygen Species: Click to Expand ⟱

Source: HalifaxProj (inhibit)

Type:

Reactive oxygen species (ROS) are highly reactive molecules that contain oxygen and can lead to oxidative stress in cells. They play a dual role in cancer biology, acting as both promoters and suppressors of cancer.
ROS can cause oxidative damage to DNA, leading to mutations that may contribute to cancer initiation and progression. So normally you want to inhibit ROS to prevent cell mutations.
However excessive ROS can induce apoptosis (programmed cell death) in cancer cells, potentially limiting tumor growth. Chemotherapy typically raises ROS.
-mitochondria is the main source of reactive oxygen species (ROS) (and the ETC is heavily related)
ROS Homeostasis in Cancer Cells and Its Potential as a Therapeutic Target

"Reactive oxygen species (ROS) are two electron reduction products of oxygen, including superoxide anion, hydrogen peroxide, hydroxyl radical, lipid peroxides, protein peroxides and peroxides formed in nucleic acids 1. They are maintained in a dynamic balance by a series of reduction-oxidation (redox) reactions in biological systems and act as signaling molecules to drive cellular regulatory pathways."
"During different stages of cancer formation, abnormal ROS levels play paradoxical roles in cell growth and death 8. A physiological concentration of ROS that maintained in equilibrium is necessary for normal cell survival. Ectopic ROS accumulation promotes cell proliferation and consequently induces malignant transformation of normal cells by initiating pathological conversion of physiological signaling networks. Excessive ROS levels lead to cell death by damaging cellular components, including proteins, lipid bilayers, and chromosomes. Therefore, both scavenging abnormally elevated ROS to prevent early neoplasia and facilitating ROS production to specifically kill cancer cells are promising anticancer therapeutic strategies, in spite of their contradictoriness and complexity."
"ROS are the collection of derivatives of molecular oxygen that occur in biology, which can be categorized into two types, free radicals and non-radical species. The non-radical species are hydrogen peroxide (H 2O 2 ), organic hydroperoxides (ROOH), singlet molecular oxygen ( 1 O 2 ), electronically excited carbonyl, ozone (O3 ), hypochlorous acid (HOCl, and hypobromous acid HOBr). Free radical species are super-oxide anion radical (O 2•−), hydroxyl radical (•OH), peroxyl radical (ROO•) and alkoxyl radical (RO•) [130]. Any imbalance of ROS can lead to adverse effects. H2 O 2 and O 2 •− are the main redox signalling agents. The cellular concentration of H2 O 2 is about 10−8 M, which is almost a thousand times more than that of O2 •−".
"Radicals are molecules with an odd number of electrons in the outer shell [393,394]. A pair of radicals can be formed by breaking a chemical bond or electron transfer between two molecules."

Recent investigations have documented that polyphenols with good antioxidant activity may exhibit pro-oxidant activity in the presence of copper ions, which can induce apoptosis in various cancer cell lines but not in normal cells. "We have shown that such cell growth inhibition by polyphenols in cancer cells is reversed by copper-specific sequestering agent neocuproine to a significant extent whereas iron and zinc chelators are relatively ineffective, thus confirming the role of endogenous copper in the cytotoxic action of polyphenols against cancer cells. Therefore, this mechanism of mobilization of endogenous copper." > Ions could be one of the important mechanisms for the cytotoxic action of plant polyphenols against cancer cells and is possibly a common mechanism for all plant polyphenols. In fact, similar results obtained with four different polyphenolic compounds in this study, namely apigenin, luteolin, EGCG, and resveratrol, strengthen this idea.
Interestingly, the normal breast epithelial MCF10A cells have earlier been shown to possess no detectable copper as opposed to breast cancer cells [24], which may explain their resistance to polyphenols apigenin- and luteolin-induced growth inhibition as observed here (Fig. 1). We have earlier proposed [25] that this preferential cytotoxicity of plant polyphenols toward cancer cells is explained by the observation made several years earlier, which showed that copper levels in cancer cells are significantly elevated in various malignancies. Thus, because of higher intracellular copper levels in cancer cells, it may be predicted that the cytotoxic concentrations of polyphenols required would be lower in these cells as compared to normal cells."

Majority of ROS are produced as a by-product of oxidative phosphorylation, high levels of ROS are detected in almost all cancers.
-It is well established that during ER stress, cytosolic calcium released from the ER is taken up by the mitochondrion to stimulate ROS overgeneration and the release of cytochrome c, both of which lead to apoptosis.

Note: Products that may raise ROS can be found using this database, by:
Filtering on the target of ROS, and selecting the Effect Direction of ↑

Targets to raise ROS (to kill cancer cells):
• NADPH oxidases (NOX): NOX enzymes are involved in the production of ROS.
    -Targeting NOX enzymes can increase ROS levels and induce cancer cell death.
    -eNOX2 inhibition leads to a high NADH/NAD⁺ ratio which can lead to increased ROS
• Mitochondrial complex I: Inhibiting can increase ROS production
• P53: Activating p53 can increase ROS levels(by inducing the expression of pro-oxidant genes)
• Nrf2 inhibition: regulates the expression of antioxidant genes. Inhibiting Nrf2 can increase ROS levels
• Glutathione (GSH): an antioxidant. Depleting GSH can increase ROS levels
• Catalase: Catalase converts H2O2 into H2O+O. Inhibiting catalase can increase ROS levels
• SOD1: converts superoxide into hydrogen peroxide. Inhibiting SOD1 can increase ROS levels
• PI3K/AKT pathway: regulates cell survival and metabolism. Inhibiting can increase ROS levels
• HIF-1α inhibition: regulates genes involved in metabolism and angiogenesis. Inhibiting HIF-1α can increase ROS
• Glycolysis: Inhibiting glycolysis can increase ROS levels • Fatty acid oxidation: Cancer cells often rely on fatty acid oxidation for energy production.
-Inhibiting fatty acid oxidation can increase ROS levels
• ER stress: Endoplasmic reticulum (ER) stress can increase ROS levels
• Autophagy: process by which cells recycle damaged organelles and proteins.
-Inhibiting autophagy can increase ROS levels and induce cancer cell death.
• KEAP1/Nrf2 pathway: regulates the expression of antioxidant genes.
    -Inhibiting KEAP1 or activating Nrf2 can increase ROS levels and induce cancer cell death.
• DJ-1: regulates the expression of antioxidant genes. Inhibiting DJ-1 can increase ROS levels
• PARK2: regulates the expression of antioxidant genes. Inhibiting PARK2 can increase ROS levels
• SIRT1 inhibition:regulates the expression of antioxidant genes. Inhibiting SIRT1 can increase ROS levels
• AMPK activation: regulates energy metabolism and can increase ROS levels when activated.
• mTOR inhibition: regulates cell growth and metabolism. Inhibiting mTOR can increase ROS levels
• HSP90 inhibition: regulates protein folding and can increase ROS levels when inhibited.
• Proteasome: degrades damaged proteins. Inhibiting the proteasome can increase ROS levels
• Lipid peroxidation: a process by which lipids are oxidized, leading to the production of ROS.
    -Increasing lipid peroxidation can increase ROS levels
• Ferroptosis: form of cell death that is regulated by iron and lipid peroxidation.
    -Increasing ferroptosis can increase ROS levels
• Mitochondrial permeability transition pore (mPTP): regulates mitochondrial permeability.
    -Opening the mPTP can increase ROS levels
• BCL-2 family proteins: regulate apoptosis and can increase ROS levels when inhibited.
• Caspase-independent cell death: a form of cell death that is regulated by ROS.
    -Increasing caspase-independent cell death can increase ROS levels
• DNA damage response: regulates the repair of DNA damage. Increasing DNA damage can increase ROS
• Epigenetic regulation: process by which gene expression is regulated.
    -Increasing epigenetic regulation can increase ROS levels

-PKM2, but not PKM1, can be inhibited by direct oxidation of cysteine 358 as an adaptive response to increased intracellular reactive oxygen species (ROS)

ProOxidant Strategy:(inhibit the Mevalonate Pathway (likely will also inhibit GPx)
-HydroxyCitrate (HCA) found as supplement online and typically used in a dose of about 1.5g/day or more
-Atorvastatin typically 40-80mg/day, -Dipyridamole typically 200mg 2x/day Combined effect research
-Lycopene typically 100mg/day range (note debatable as it mainly lowers NRF2)

Dual Role of Reactive Oxygen Species and their Application in Cancer Therapy

ROS-Inducing Interventions in Cancer — Canonical + Mechanistic Reference
-generated from AI and Cancer database
ROS rating:  +++ strong | ++ moderate | + weak | ± mixed | 0 none
NRF2:        ↓ suppressed | ↑ activated | ± mixed | 0 none
Conditions:  [D] dose  [Fe] metal  [M] metabolic  [O₂] oxygen
             [L] light [F] formulation [T] tumor-type [C] combination


Item  ROS↑  NRF2  Condition  Mechanism Class  Remarks  

ROS">Piperlongumine
+++  ↓  [D][T]  ROS-dominant
Selective <span class="wphighlight">ROS</span> stressor, Prevents compensatory upregulation of NRF2, ie GSH↓



ROS">Shikonin
+++ ↓/± [D][T] ROS-dominant
<span class="wphighlight">ROS</span> + glycolysis + GPX4 inhibition



ROS">Vitamin K3 (menadione)
+++ ↓ [D] ROS-dominant
Quinone redox cycler; toxicity limits use



ROS">Copper (ionic / nano)
+++ ↓ [Fe][F] ROS-dominant
Fenton-type redox chemistry



ROS">Sodium Selenite
+++ ↓ [D] ROS-dominant
Pro-oxidant, depletes GSH



ROS">Juglone
+++ ↓ [D] ROS-dominant
Strong quinone <span class="wphighlight">ROS</span> chemistry



ROS">Auranofin
+++ ↓ [D] ROS-dominant
TrxR inhibition → redox collapse



ROS">Photodynamic Therapy (PDT)
+++ 0 [L][O₂] ROS-dominant
Singlet oxygen is core cytotoxic mechanism



ROS">Radiotherapy / Radiation
+++ 0 [O₂] ROS-dominant
DNA damage largely via <span class="wphighlight">ROS</span>



ROS">Doxorubicin
+++ ↓ [D] ROS-dominant
Chemo; redox cycling + mitochondrial <span class="wphighlight">ROS</span>



ROS">Cisplatin
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span> contributes to DNA/protein damage



ROS">Salinomycin
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span>-mediated CSC toxicity



ROS">Artemisinin / DHA
++ ↓ [Fe][T] ROS-dominant
Iron-activated radical generation



ROS">Sulfasalazine
++ ↓ [C][T] ROS-dominant
Ferroptosis; xCT inhibition → lipid <span class="wphighlight">ROS</span>



ROS">FMD / fasting
++ ↓ [M][C][O₂] ROS-dominant
Metabolic stress → mitochondrial <span class="wphighlight">ROS</span>



ROS">Vitamin C (pharmacologic)
++ ↓ [Fe][D] ROS-dominant
Extracellular H₂O₂ at high dose



ROS">Silver nanoparticles
++ ± [F][D] ROS-dominant
<span class="wphighlight">ROS</span> common; selectivity unreliable



ROS">Gambogic acid
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span>-mediated apoptosis



ROS">Parthenolide
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span> + NF-κB suppression



ROS">Plumbagin
++ ↓ [D] ROS-dominant
Quinone <span class="wphighlight">ROS</span> driver



ROS">Allicin
++ ↓ [D] ROS-dominant
Thiol-reactive oxidative stress



ROS">Ashwagandha (Withaferin A)
++ ↓ [D][T] ROS-dominant
<span class="wphighlight">ROS</span>-mediated apoptosis



ROS">Berberine
++ ↓ [D][M] ROS-dominant
Mitochondrial <span class="wphighlight">ROS</span> induction



ROS">PEITC
++ ↓ [D][C] ROS-dominant
GSH depletion + <span class="wphighlight">ROS</span>



ROS">Methionine restriction
+ ↓ [M][C][T] ROS-secondary
Redox vulnerability increased; <span class="wphighlight">ROS</span> indirect



ROS">DCA
+ ± [M][T] ROS-secondary
<span class="wphighlight">ROS</span> via forced OXPHOS



ROS">Capsaicin
+ ± [D][T] ROS-secondary
Ca²⁺ stress → <span class="wphighlight">ROS</span>



ROS">Galloflavin
+ 0 [D] ROS-secondary
<span class="wphighlight">ROS</span> not primary driver



ROS">Piperine
+ ± [D][F] ROS-secondary
Weak <span class="wphighlight">ROS</span> induction



ROS">Propyl gallate
+ ↓ [D] ROS-secondary
Pro-oxidant at high dose



ROS">Scoulerine
+ ? [D][T] ROS-secondary
Sparse <span class="wphighlight">ROS</span> data



ROS">Thymoquinone
± ± [D][T] Dual redox
Antioxidant ↔ pro-oxidant switch



ROS">Emodin
± ± [D][T] Dual redox
Not cancer-exclusive



ROS">Alpha-lipoic acid (ALA)
± ↑ [D][M] NRF2-dominant
Antioxidant at low dose



ROS">Curcumin
± ↑/↓ [D][F] NRF2-dominant
Hormetic redox behavior



ROS">EGCG
± ↑/↓ [D][O₂] NRF2-dominant
Auto-oxidation artifacts common



ROS">Quercetin
± ↑/↓ [D][Fe] NRF2-dominant
GSH-dependent cycling



ROS">Resveratrol
± ↑ [D][M] NRF2-dominant
<span class="wphighlight">ROS</span> only at high dose



ROS">Sulforaphane
± ↑↑ [D] NRF2-dominant
Strong NRF2 activator



ROS">Lycopene
0 ↑ — Antioxidant
Consistently antioxidant



ROS">Rosmarinic acid
0 ↑ — Antioxidant
Primarily antioxidant



ROS">Citrate
0 0 — Neutral
Metabolic; not a <span class="wphighlight">ROS</span> agent

Scientific Papers found: Click to Expand⟱

4071-

FA,

Folate and Alzheimer: when time matters

Review,

AD,

*cognitive↑, *ROS↓, *Ca+2↓, *p‑tau↓, *Aβ↓,

4037-

VitB12,

FA,

Mechanistic Link between Vitamin B12 and Alzheimer’s Disease

Review,

AD,

*antiOx↑, *ROS↓, *GSH↑, *Inflam↓, *IL6↓, *TNF-α↓, *other↑, *other↑, *other↑, *Aβ↓, *memory↑, *p‑tau↓, *APP↓, *BACE↓, *ATP↑, *neuroP↑,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:

Total Targets: 0

Pathway results for Effect on Normal Cells:

Functional Outcomes(tgid=23) ⓘ

cognitive↑, 1, memory↑, 1, neuroP↑, 1,
Total Targets: 17

Scientific Paper Hit Count for: ROS, Reactive Oxygen Species

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:80  Target#:275  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

Folic Acid, Vit B9 / ROS Cancer Research Results

Folic Acid Mechanistic Profile

Alzheimer’s Disease Mechanistic Profile

Pathway results for Effect on Cancer / Diseased Cells:

Pathway results for Effect on Normal Cells:

Redox & Oxidative Stress(tgid=1) ⓘ

Mitochondria & Bioenergetics(tgid=3) ⓘ

Transcription & Epigenetics(tgid=7) ⓘ

Migration(tgid=13) ⓘ

Immune & Inflammatory Signaling(tgid=16) ⓘ

Synaptic & Neurotransmission(tgid=18) ⓘ

Protein Aggregation(tgid=19) ⓘ

Clinical Biomarkers(tgid=22) ⓘ

Functional Outcomes(tgid=23) ⓘ

Home Page